Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
14.80
+0.14 (0.95%)
At close: Apr 17, 2026, 4:00 PM EDT
14.71
-0.09 (-0.61%)
After-hours: Apr 17, 2026, 7:52 PM EDT
Viridian Therapeutics Revenue
In the year 2025, Viridian Therapeutics had annual revenue of $70.85M with 23,359.93% growth. Viridian Therapeutics had revenue of $132.00K in the quarter ending December 31, 2025, with 83.33% growth.
Revenue (ttm)
$70.85M
Revenue Growth
+23,359.93%
P/S Ratio
21.35
Revenue / Employee
$281,147
Employees
252
Market Cap
1.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.85M | 70.55M | 23,359.93% |
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | 4.46M | -3.93M | -46.80% |
| Dec 31, 2018 | 8.39M | 4.38M | 109.49% |
| Dec 31, 2017 | 4.00M | 526.00K | 15.13% |
| Dec 31, 2016 | 3.48M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.12B |
| Ardelyx | 407.32M |
| Immunocore Holdings | 400.02M |
| Iovance Biotherapeutics | 263.50M |
| Monte Rosa Therapeutics | 123.67M |
| Immatics | 56.67M |
| Generate Biomedicines | 31.89M |
| AtaiBeckley | 4.09M |
VRDN News
- 12 days ago - Why Is Viridian Therapeutics Stock Sinking Monday? - Benzinga
- 12 days ago - Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study. - Barrons
- 19 days ago - Why Is Viridian Therapeutics Stock Falling Monday? - Benzinga
- 19 days ago - Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease - Business Wire
- 7 weeks ago - Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 3 months ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Viridian Therapeutics Prepares for Transformational 2026 - Business Wire
- 4 months ago - Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire